Resolution Therapeutics was founded in August 2020 to develop engineered macrophage cell therapies.

Syncona founded Resolution following a two year collaboration with researchers at the University of Edinburgh. The company is developing macrophage cell therapies to repair organ damage, including treatment of end-stage chronic liver disease. Macrophages are cells of the innate immune system which orchestrate the body’s defence against infection and injury.


Company Details


Edward Hodgkin


Stuart Forbes
John Campbell

Syncona Representatives:

Martin Murphy
Edward Hodgkin
Gonzalo Garcia